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Universitätsmedizin, Berlin, Germany, 10 Research Center Karaganda Medical University, Karagandy, Kazakhstan,
11 Structural and Computational Biology Unit, The European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
Introduction: Probiotics and prebiotics are widely used for recovery of the human gut
microbiome after antibiotic treatment. High antibiotic usage is especially common in
children with developing microbiome. We hypothesized that dry Mare’s milk, which is rich
in biologically active substances without containing live bacteria, could be used as a
prebiotic in promoting microbial diversity following antibiotic treatment in children. The
present pilot study aims to determine the impacts of dry Mare’s milk on the diversity of gut
bacterial communities when administered during antibiotic treatment and throughout the
subsequent recovery phase.
Methods: Six children aged 4 to 5 years and diagnosed with bilateral bronchopneumonia
were prescribed cephalosporin antibiotics. During the 60 days of the study, three children
consumed dry Mare’s milk whereas the other three did not. Fecal samples were collected
daily during antibiotic therapy and every 5 days after antibiotic therapy. Total DNA was
isolated and taxonomic composition of gut microbiota was analyzed by 16S rRNA
amplicon sequencing. To assess the immune status of the gut, stool samples were
analyzed by bead-based multiplex assays.
Results: Mare’s milk treatment seems to prevent the bloom of Mollicutes, while
preventing the loss of Coriobacteriales. Immunological analysis of the stool reveals an
effect of Mare’s milk on local immune parameters under the present conditions.
Keywords: mare’s milk, microbiome, 16S rRNA gene sequencing, collateral antibiotic effect, intestinal immunitygy | www.frontiersin.org April 2021 | Volume 11 | Article 6227351
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Advances in studies of the human microbiome have shown that
homeostasis of the intestinal microbiota is critical to maintaining
health, especially in a developing organism. Antibiotics, which
act to suppress pathogenic bacteria, and are usually prescribed
for infections and infectious complications, also inevitably affect
the normal microbiota. Antibiotics of various pharmacological
groups have different effects on the composition and function of
intestinal bacteria and lead to different consequences. It has been
shown that changes in the intestinal microbiome in early
childhood could play a role in the development of pathologies
such as inflammatory bowel diseases, allergies, lactose intolerance,
obesity, cardiometabolic disease, and even mental disorders
including late dyslalia and autism (Adamek et al.; Kushugulova
et al., 2018a; Lee et al., 2018; Algazina et al., 2019; Pulikkan et al.,
2019; Askarova et al., 2020)
It is known that destabilization of the microbiome
composition, for example by antibiotics, results in the disruption
of important microbiota functions, such as its trophic potential, its
provision of short-chain fatty acids (SCFAs) to colonocytes, or its
participation in bile acid metabolism (Taylor and Green, 2018;
Parada Venegas et al., 2019). After an antibiotic course, it has been
shown that bile acid and steroid metabolism are likely to decrease,
while the metabolism of sugars and starch is likely to increase
(Antunes et al., 2011). Destabilization leads to the disruption of
interactions in the colonocyte-microbiota system, a decrease in the
protective properties of the mucin layer and, as a consequence of
these factors, a decrease in the colonization resistance of the
microbiota with concomitantly increased risk for the growth of
an opportunistic/pathogenic flora (Asha et al., 2006; Högenauer
et al., 2006).
Antibiotic therapy has profound effect on the composition of
the microbiome (Palleja et al., 2018). This can be especially
deleterious in young children, where the destabilization of the
microbiome can become a trigger factor in the development of
chronic diseases. Antibiotics are believed to reduce colonization
resistance against enterobacteria, such as Escherichia coli and
Salmonella enterica, by increasing the inflammatory tone of the
intestinal mucosa (Spees et al., 2013). Various studies have shown
that different types of microbiome shifts can induce different types
of immune cells, and different antibiotics can have different
cytokine responses (Kosiewicz et al., 2011; Zheng et al., 2020).
The mechanisms of these interactions are still relatively poorly
defined in human studies.
In order to prevent damage to or restore the intestinal
microbiome, probiotics and prebiotics are often used. Under
certain circumstances use of probiotics could lead to severe
complications such as endo cardiomyopathies or even
septicemia (Lacaille et al., 2015; Naqvi et al., 2018; Suez et al.,
2018) however, high intraindividual persistence alongside high
interindividual variability in rapidly renewing microbiomes
suggest that probiotics could be personalized based on
knowledge of individual enterotype or other metrics of
idiosyncrasy (Christensen et al., 2018; Costea et al., 2018; Yang
et al., 2019; Wang et al., 2020) The wider use of functional foodsFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 2or supplements that do not contain living microbial cells, such as
prebiotics and metabiotics (Shenderov, 2013), may constitute a
safer complementary practice to probiotic approaches, especially
in vulnerable subjects, such as children.
Mare’s milk could be beneficial for recovering perturbed
intestinal microbiome composition due to its prebiotic and
immunomodulatory effects (Foekel et al., 2009; Wulijideligen
Asahina et al., 2012; Suez et al., 2018) Antimicrobial activity of
mare’s milk is associated with a high abundance of lysozymes,
immunoglobulins, lactoperoxidases, and lactoferrin (Hancock
et al., 2002; Pieszka et al., 2016; Kushugulova et al., 2018b).
Additionally, it contains biologically active substances important
for the intestinal microbiome and is close in biochemical
composition to mother’s milk (Jastrzebska et al., 2017). Several
studies have shown that breast milk feeding helps to recover the
intestinal microbiota after intranatal and postnatal antibiotic
therapy due to pre/probiotic and immunomodulatory effects, as
well as to decrease the antibiotic resistance gene load (Azad et al.,
2016; Pärnänen et al., 2018; Järvinen et al., 2019). We hypothesize
that mare’s milk can help promote microbial diversity following
antibiotic treatment. The present pilot study thus sought to
determine the impacts of mare’s milk treatment on the diversity
of the gut bacterial community when taken during antibiotic
treatment and throughout the subsequent recovery phase,
compared to antibiotic exposure in the absence of any
other treatment.MATERIALS AND METHODS
Patients
This study was approved by the regional committee for medical
research ethics in the National Laboratory Astana, Nazarbayev
University (Protocol number 20 from 22.09.2017, IORG0006963),
and registered on ClinicalTrials.gov under study identifier
NCT03657836. Clinical investigations have been conducted
according to the principles of the Declaration of Helsinki. Written
informed consent for sample collection and subsequent analyses
was obtained from the parents of all participants. Recruitment of
patients was carried out in the Pulmonology Department of the First
Children’s City Hospital, Nur-Sultan, Kazakhstan from September
2018 to August 2019.
The study includes six children between the age of 4 to 5 years
diagnosed with bilateral bronchopneumonia who met the
inclusion and exclusion criteria. Inclusion criteria were patients
of both sexes aged 4-5 years; the voluntary informed consent
from the parents of the child to participate in the study;
established diagnosis of acute upper respiratory tract disease
with prescription of cephalosporin antibiotics; the duration of
symptoms of acute upper respiratory tract disease no more than
72 hours before antibiotic treatment; and absence of prescription
of antibacterial drugs during the last three months. Exclusion
criteria were: a history of taking probiotics and antibiotics three
months before admission to hospital; anamnesis of chronic
diseases of the digestive tract and/or of any surgeries on theApril 2021 | Volume 11 | Article 622735
Kushugulova et al. Milk Reduces Side Antibiotic Effectdigestive tract; no history of concomitant diseases of the kidneys,
liver, cardiovascular, chronic respiratory and other body systems,
cancer, mental and decompensated endocrine diseases,
tuberculosis, human immunodeficiency virus (HIV) infection;
patient involvement in other clinical trials within the last three
months; and finally lack of consent. The study lasted 60 days
(Figure 1); patients were discharged on day seven and then
observed on an outpatient basis. At the time of admission and on
day 60 of the study, all patients were medically examined, which
included a general blood test (hemoglobin (Hb), erythrocytes,
thrombocytes, leukocytes, neutrophils, lymphocytes, monocytes,
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)),
stool test (coprogram), and fecal calprotectin quantification.
During prescription of antibiotics of the cephalosporin group
severity of the disease course and body weight were taken into
account. Three out of six patients were additionally instructed to
consume 40 grams per day of freeze-dried mare’s milk by
dilution in warm water at any desired dilution during the day.
Children were randomly assigned to a group which, along with
standard therapy, received this auxiliary treatment in the form of
reconstructed freeze-dried mare’s milk, which is encoded as MM
(MM = mare’s milk) or to the control group, given antibiotics
only (AB). In the control group, parents were instructed to
refrain from giving their children any probiotics, prebiotics, orFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 3other functional products during the entire study period (60
days). Additionally, for 60 days during the collection of
biomaterials, the investigator further advised parents to refrain
from probiotics.
Composition of the Mare’s Milk
The product is a freeze-dried powder made from fresh mare’s
milk by vacuum drying. The product is manufactured at the
mare’s milk factory of Eurasia invest Ltd LLP. The product was
provided for the study participants in 20-gram sachets. Product
expertise was conducted at the Kazakh Academy of Nutrition
and SGS-CSTC Standards Technical Services Co., Ltd.
(Shanghai). According to the results of the latter, sublimated
mare’s milk contains the following micronutrients: all
interchangeable and essential amino acids 17.18% (GB
5009.124-2016), saturated (3.54 g/100 g) and unsaturated fatty
acids (5.24 g/100 g), w-3 fatty acid (2.17 g/100 g) and w-6 fatty
acid (1.03 g/100 g), SCFA (0.02-2.13 g/100 g), vitamin B12
(0.77 mg/100 g), retinol (41 mg/100 g), a-Tocopherol (0.31 mg/
100 g), vitamin E (0.31 mg/100 g), pantothenic acid (3.09×103
mg/100 g), vitamin B6 (as pyridoxine) (0.155 mg/100 g), folic acid
(10.1 mg/100 g), vitamin C (97 mg/100 g), zinc (Zn) (18.4 mg/kg),
calcium (Ca) (6.66×103 mg/kg), iron (Fe) (2.3 mg/kg), aspartic
acid (1.46%), threonine (0.7%), serine (0.97%), glutamic acidFIGURE 1 | Study design Six children (age 3.9 ± 0.7) without previous antibiotic exposure were treated with a cephalosporin because of bronchopneumonia. Three
children were randomly assigned to the intervention group and administered mare’s milk daily for the entirety of the 5-day antibiotic intervention as well as the 55
days following. Microbiome sampling (stool or swab) and other phenotyping were performed, as shown in the diagram for both study arms.April 2021 | Volume 11 | Article 622735
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important for the intestinal microbiome, such as lysozyme,
lactoferrin, and lactadherin (Pieszka et al., 2016).
Multiplex Immunoassay
To evaluate the immunological parameters, 3-4 mg of frozen
feces of the samples were diluted in 200 ml of phosphate buffer,
centrifuged, and the supernatant was analyzed using the
manufacturer’s protocol. To analyze multiple cytokine and
chemokine, we used the MILLIPLEX MAP Human Cytokine/
Chemokine Magnetic Bead Panel, and for immunoglobulin
isotyping the Milliplex® magnetic bead panel (HGAMMAG-
301K-06, EMD Millipore Corp., Billerica, MA) was used.
Samples were analyzed on a Bio-Plex 3D suspension
array system.
Sample Collection and Data Analysis
Fecal samples were collected by the patients using swabs or tubes.
Feces was deposited into a toilet hat and immediately sampled,
then stored frozen at approximately −20°C in bags with a
refrigerant. Biomaterial sampling was carried out by two
methods because many children had constipation after
antibiotic therapy. We used special bags with refrigerant inside
which tubes were frozen, allowing us to transport them without
violating the temperature regime. Samples were subsequently
transferred to the laboratory and stored at −80°C until processed.
Samples from patients were obtained prior to antibiotic therapy
and between 1 to 60 days of the study, with daily collection until
day 6, and thereafter collection every five days until day 60.
DNA was extracted from fecal samples using the Zymo
Research Quick-DNA™ Fecal/Soil Microbe. Microprep Kit
(Cat.No.: D6012), from swab samples using ZymoBiomics
DNA Microprep kit (Cat No.: D4301), according to the
manufacturer’s instructions. Fecal DNA concentrations were
measured using a Nanodrop 2000/2000с (ThermoFisher).
Sequencing libraries were prepared by amplifying the V1-V3
region of the 16S rRNA gene according to the manufacturer’s
instructions. The libraries’ quality was quantified on a Qubit 2.0
instrument using the dsDNA BR Qubit assay kit (ThermoFisher,
32853). Sequencing was performed as previously described (Su
et al., 2018) on an Illumina MiSeq platform using 2 × 150 bp
paired-end reads.
Statistics
We performed data analysis using the less operational taxonomic
units scripts (LotuS) pipeline (Hildebrand et al., 2014). The
LotuS pipeline performs quality controls, sequence trimming
and filtering, clustering OTUs, and taxonomic annotation from
amplicons of metagenomic samples. LotuS was used with the
sdm MiSeq configuration for sequence preprocessing.
Taxonomic assignment of OTUs was performed using the
databases SILVA (v138), greengenes (v13-5) and HITdb
(v1.00) incrementally. Results were normalized using the
rarefaction toolkit (RTK) pipeline with default parameters
(Saary et al., 2017), to the lowest read count of the samples
included following quality control. As a measure of alpha
diversity, the Shannon index was calculated by RTK. Data wasFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4reformatted for analysis using the R statistical programming
environment by means of custom Perl scripts. Beta diversity was
assessed using the R package vegan (Bates et al., 2015; Oksanen
et al., 2019), including PERMANOVA analysis and generation of
distance metrics. Further analysis of taxonomic and immune cell
data was conducted using linear mixed models compared using
likelihood ratio tests as implemented in R packages lme4 and
lmtest (Zeileis and Hothorn, 2002; Bates et al., 2015), using the
lrtest function and ensuring REML approximation was not used
Plots were generated using the ggplot2 R package (Hadley
Wickham, 2016). For each analyzed variable, the Cliff’s delta
effect size was evaluated by using the R package “orddom”
(Rogmann, 2013). For results of the multiplex assay, statistical
analysis was carried out using the R psych package (William
Revelle, 2017) and standard t-tests. FDR adjustment was done
using the Benjamini-Hochberg method.RESULTS
At the time of discharge from the clinic, all patients exhibited a
positive clinical response to antibiotic treatment, as assessed by
qualitative amelioration of appetite and sleep, and normalization
of body temperature. At baseline there were no significant
differences in most of the clinical parameters (p < 0.17, p < 0.08,
p < 0.45, and p < 0.51 for age, ESR, CRP, and fecal calprotectin,
respectively), though white blood cell count was higher in the MM
group as compared to the AB group (p < 0.01). By the 60th day of
the study, all blood parameters in both groups were restored to
normal and were not different between the two groups (Table 1).
As expected, cephalosporin treatment led to a profound gut
bacterial depletion. We observe an altered taxonomic composition
during treatment even though no significant impact on alpha
diversity (Shannon index) could be demonstrated using the
present dataset (Figure S1), which is likely a statistical power
limitation due to the small sample size. Similarly, while trends in
shifting abundance are seen in various taxa -many persisting by the
end of the study period - these changes do not achieve significance
in the present pilot.
PERMANOVA analysis of beta diversity (Bray-Curtis
intersample dissimilarities) revealed a significant difference
between samples from the AB and MM groups (Figure 2),
including all time points following the cessation of antibiotic therapy.TABLE 1 | Baseline.
Name of indicators AB MM
baseline 60 day baseline 60 day
n=3 n=3 n=3 n=3
Age 4.4 4.4 3.5 3.5
White Blood Cell,
^109/L
10.4 ± 1.21 8.0 ± 0.9 19,1 ± 1.24 8.9 ± 3.9
ESR, mm/h 9.33 ± 3.48 8.3 ± 6.8 20.6 ± 3.33 8.0 ± 6.2
CRP, mg/L 7.28 ± 4.73 1.8 ± 1.9 30.74 ± 24.74 1.45 ± 0.35
Fecal Calprotectin,
mg/g
51.3 ± 16.2 19.1 ± 14.9 30.02 ± 23.76 25.6 ± 35.8April 2021 | Volume 11 | Article 622735
Kushugulova et al. Milk Reduces Side Antibiotic EffectWhile the small sample size limits our statistical power, clear
trends are observable throughout the full length of the study.
This allows us to assess the influence of the intervention on the
gut abundance of specific taxa (Figure 3). Compositional
bacterial microbiome analysis showed that antibiotic therapy
positively correlates with the phylum Firmicutes (| d | = 0.49;
FDR < 0.30), mostly due to the order Clostridiales (| d | = 0.43;
p < 0.05; FDR < 0.39) and negatively correlated with
Bacteroidetes (| d | = -0.39; FDR < 0.41). The abundance of
Erysipelotrichia decreases after exposure to antibiotics (| d | = -
0.48; p < 0.02; FDR < 0.43) and is still reduced by the end of the
study period of 50-60 days (| d | = -0.37; FDR < 0.33). The
abundance of Deltaproteobacteria increases at the background of
antibiotic therapy compared with baseline (| d | = 0.35;
FDR<0.36) and continues to trend until the end of the study
period; effect size comparing baseline 50-60 days was | d | = 0.54
(FDR<0.35). At the genus level, the abundance of Hungatella
(| d | = ‑0.28; p < 0.02; FDR < 0.44) and Lachnoclostridium
(| d | = -0.36; p < 0.03; FDR < 0.91) tends to decrease. We observe
a trending negative correlation between antibiotic use and the
abundance of an unclassified Bacteroides (| d | = -0.38; p < 0.005;
FDR < 0.67), genera of family Gastranaerophilales (| d | = 0.28;
p < 0.051; FDR < 0.67), and a positive correlation for Escherichia-
Shigella (| d | = -0.27; p < 0.04; FDR < 0.67).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5During the entire study period in group AB, the abundance of
Lachnosp i raceae UCG-004 , Phasco larc tobac ter ium ,
Ruminococcaceae UCG-004, Ruminococcaceae UCG-005, and
Fusicatenibacter is higher than at the baseline for genera
(Table S1). Despite limited statistical power in our pilot
sample, analysis of gut taxonomic composition on the class
level revealed significant (Benjamini-Hochberg FDR corrected
p-values Q < 0.1) differences in the post-antibiotic trajectories of
MM and AB samples, under mixed-effect model comparisons
taking individual variability, time point, and stool/swab sample
status into account. Mare’s milk treatment appears here to
prevent the bloom of Mollicutes while preventing the loss of
Coriobacteriales (Figure 4).
In theMMgroup,we insteadobserve a significant increase of the
abundance of Coriobacteriales, which are in the phylum of
Actinobacteria and consist of two families, the Coriobacteriaceae
and Atopobiaceae. Coriobacteriales belong to the commensal flora
and typically inhabit the oral cavity, gastrointestinal tract, and
genital tract. In the intestines, the representatives of
Coriobacteriales order are the Coriobacteriaceae family, which
performs important functions, such as the conversion of bile salts
and steroids, as well as the activation of food polyphenols (Clavel
et al., 2014).
To determine trends in local intestinal immunity, we
calculated the Cliff’s delta effect sizes for cytokines/chemokines
comparing baseline with days 3, 5, 10, 20, and 60 of the study
(Table S2).
On day 3 of the study, we observe the level of IgG3 lower than
at the baseline (| d | = -1.0; p < 0.03; FDR < 0.66). On day 10 of
the study the decreased level of Interleukin 8 (IL8) (| d | = -1.0;
p < 0.03; FDR < 0.34) and Granulocyte-Colony Stimulating
Factor (G-CSF) (| d | = -1.0; p < 0.03; FDR < 0.34).
Antibiotic therapy led to significant decreases of anti-
inflammatory cytokine/chemokine levels.
The analysis of absolute numbers of the pro-inflammatory
and inflammatory cytokines/chemokines already on the 3rd day
of the antibiotic therapy showed the changes in Macrophage
Inflammatory Proteins aalpha (MIP1a) (FDR < 0.01), Tumor
Necrosis Factor alpha (TNFa) (FDR < 0.02), GCSF (FDR < 0.09),
IL1RA (FDR < 0.09) (Table S3). Transforming Growth Factor
Alpha (TGFa) in healthy subjects strengthens proliferation of
enterocytes and induces an intestinal adaptation. Here we find
that after antibiotic therapy, the TGFa is decreased significantly
by the 20th day of the study (FDR < 0.003) and remains low
compared with the data before the start of antibiotic therapy
until the 60th day of the study (FDR < 0.001). By the end of the
study, we observe a decrease of soluble Cluster of Differentiation
40 ligand (sCD40L) level (FDR < 0.03).
During the entire period observed after antibiotic therapy, a
significant decrease in the level of immunoglobulins is noted
(Table S4); on day 3 in the AB group, levels of IgA (FDR < 0.07),
IgG3 (FDR < 0.05), and IgM (FDR < 0.15) were significantly
reduced. The trend persists throughout the observation period.
In the group receiving mare’s milk, we observe a significant
change in Vascular Endothelial Growth Factor (VEGF) during
all study periods (p < 0.06, FDR < 0.10). Some indicatorsFIGURE 2 | Multivariate analysis of gut composition shifts. Principal
Coordinates Analysis (PCoA) of gut composition (samples post-antibiotic only,
replicates not shown) analyzed using Bray-Curtis distances applied to rarefied
gut 16S OTU data. The first two dimensions capturing the data distance
space significantly (PERMANOVA P < 0.001, with parameters in order:
intervention, sample ID, swab vs. stool sample, and time point) separates
mare’s milk-treated samples from controls. Marginal plots show this
distribution on both axes, and lines connect labeled time points of samples
from the same subject. On the overall level, gut composition post-antibiotics
differs between controls and MM-treated subjects.April 2021 | Volume 11 | Article 622735
Kushugulova et al. Milk Reduces Side Antibiotic Effectsignificantly change by the 10th day of the study, IL3 (p < 0.03,
FDR < 0.11), IL8 (p < 0.002, FDR < 0.005), TNFa (p < 0.02,
FDR < 0.07), GCSF (p < 0.03, FDR < 0.11), which indicates an
active inflammatory process in the body. However, in the
following days, no significant changes were observed. Only
the level of immunoglobulin G3 is reduced during the entire
study period (p < 0.04, FDR < 0.08). Thus, taken together,
complex immunological analysis reveals an effect of mare’s milk
on local immune parameters under the present conditions
(Figure 5).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6As native gut inhabitants, opportunistic flora does not
typically cause complications in a healthy host. However,
immunosuppression may allow these bacteria to proliferate at
a relative advantage in the intestinal tract and cause disseminated
infections. In response to antibiotic therapy, we do observe
changes in immunological parameters. However, it should be
taken into account that at the time of the first measurements of
the immune status, all patients had an inflammatory process as
reflected in their blood counts on the first day of the study. To
further elucidate, it will be necessary to expand this research andFIGURE 3 | Overview of gut composition shifts at phylum level. The diagram shows gut abundance of different bacterial phyla, on average across the cohort
(N=6, top panel), the intervention samples (N=3, middle panel), and the control samples (N=3, bottom panel). Marker size and intensity show average gut
abundances with direction (upwards-facing: enriched, downwards-facing: depleted) compared to baseline (round markers). Most trends under the intervention
(antibiotics: first 5 days; mare’s milk: all 60 days) are seen in both groups but with exceptions. Various taxa are gained or lost below detection threshold during
the observation period.April 2021 | Volume 11 | Article 622735
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group with and without mare’s milk consumption.DISCUSSION
The human gut microbiome has coevolved with its host and is
shaped by its diet and immune status, as well as by local
competition of bacterial cells for an ecological niche and access
to nutrients. A perturbed microbiome has a decreased capacity to
perform its vital functions, such as digestive and synthetic
activity, as well as providing colonization resistance and to
regulate the body’s immune system. Antibiotic treatment has
been shown to have major impact on the overall taxonomic
composition of gut microbiota. Here, we studied the potential
protective properties of mare’s milk on ameliorating adverse
effects of antibiotic therapy on the gut microbiome.
We observe a perturbed microbiota following a short-term
administration of cephalosporins. The effect of the antibiotic on
the intestinal microbiota was pervasive and quick, with a loss of
diversity and a change in the composition of the community seen
only two days after the introduction of cephalosporins (Bhalodi
et al., 2019). While the communities began to return to their
original state by the 10th day of the study, this return was not
fully accomplished, in line with other recent work (Palleja et al.,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 72018; Suez et al., 2018). In this study, the intestinal microbiota
before antibiotic treatment consisted mainly of bacteria from the
phyla Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria,
and Epsilonbacteraeota. Post-antibiotics, fecal samples from the
AB group exhibited an enrichment of Firmicutes and
Tenericutes (Figure 6).
Further taxonomic characterization revealed the prevention
o f g rowth o f Mol l i cu t e s in the MM group . The
class Mollicutes contains more than forty known pathogens in
humans and animals. Since Mollicutes class representatives lack
cell walls, the main classes of antimicrobial agents, such as beta-
lactam antibiotics, glycopeptides, and fosfomycin, do not affect
them (Chernova et al., 2016), this may explain the relatively high
growth of these organisms in our studies as they would possess a
relative advantage. Furthermore, beta-lactam antibiotics like the
cephalosporins tested here are immunosuppressive, with the
resulting inflammatory process potentially caused by
representatives of the Mollicutes class (Huegin et al., 1986;
Villa et al., 1991). Some Mollicutes cause human and animal
diseases characterized by lymphoid infiltrates, immunosuppression,
autoantibody production, and they have been associated with
obesity (Turnbaugh et al., 2008). We propose that the inhibition
effect we here see onMollicutes under mare’s milk interventionmay
be due to lysozyme and lactoferrin acting as antimicrobial
molecules, as well as through stimulating growth of commensalA B
FIGURE 4 | Specific gut orders enriched and depleted. Two bacterial orders show significantly altered abundance between MM-treated subjects and controls in
post-antibiotic samples (replicates removed) tested using nested mixed models compared using a likelihood ratio test, controlling for donor as random effect,
timepoint and stool vs. swab as fixed effects. (A) Figure shows Mollicutes gut abundance of the subjects, labeled red (N=3, controls) or blue (N=3, MM), shown as
time trajectories and boxplots. (B) Figure shows Coriobacteriales gut abundance of the subjects, labeled red (N=3, controls) or blue (N=3, MM), shown as time
trajectories and boxplots.April 2021 | Volume 11 | Article 622735
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potential of dietary interventions to reduce collateral antibiotic
effects on the microbiome is a growing area of research. Our
exploratory study is one of the first microbiome analyses
assessing the influence of mare’s milk. It was previously reportedFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 8(Foekel et al., 2009; Pieszka et al., 2015; Shariatikia et al., 2017) that
mare’s milk has beneficial effects on human health, and we
proposed that its rich content of biologically active substances are
beneficial for microbiome inhabitants. Our present preliminary
results suggest that mare’s milk supplementation is associated with
an improvement in post-antibiotic microbiome state relative to
no intervention.
A significant difference in the trajectories of the MM and AB
groups was nevertheless visible both in multivariate and
univariate analyses of microbiome composition, including
enrichment of Coriobacteriales bacteria. Members of this order
are typically sensitive to antibiotic exposure, and apparently,
mare’s milk contains substances able to support their growth.
Bacterial components of the gut microbiome have been
previously shown to interact with the mucosal and systemic
immune systems through specific pathways and cytokines. The
mechanisms underlying the microbiome-cytokine interaction
may involve mediation by the metabolites originating in the gut
(Schirmer et al., 2016). It has further previously been observed
that antibiotic-induced perturbations of the microbiome can
modulate the inflammatory state of the host. To understand
how antibiotics affect immune status, previous researchers
analyzed effects of monoantibiotics or mixtures of broad-
spectrum antibiotics (Sun et al., 2019) in experimental studies in
various laboratory animal models, as well as monoantibiotics
specific for gram-positive (Strzepa et al., 2017) or gram-negative
bacteria (Shi et al., 2018). Thus, these previous studies offer
potential scenarios for how microbiome-immune system
interplay may be salient under the conditions we test here, both
with regards to antibiotics administration and to possible partial
mitigation of dysbiosis from the MM intervention.
Antibiotics, directly or indirectly through exposure to the
intestinal microflora, affect local intestinal immunity. In the vast
majority of cases, cytokines are short-acting mediators of local cell
interactions in physiological and pathological processes in tissues
(Feldmann, 2008). Cytokines are involved in autocrine, paracrine
and endocrine signaling as immunomodulating agents; autocrineFIGURE 6 | Dynamics of changes in abundance at the phylum level (Effect size Cliff’s delta).FIGURE 5 | Multivariate analysis of immune shifts. Principal Coordinates
Analysis (PCoA) of gut composition (samples post-antibiotic only, replicates
not shown) analyzed using Bray-Curtis distances applied to immune
measurements. The first two dimensions capturing the data distance space
significantly (PERMANOVA P < 0.001, with parameters in order: intervention,
participant identity, and time point) separates mare’s milk-treated samples
from controls.April 2021 | Volume 11 | Article 622735
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itself; paracrine, where the cytokine acts on the cell located next to
the producer call; and endocrine effect, this is a remote or systemic
effect when the cytokine reaches the target cell through the blood
(García Morán et al., 2013). The endocrine effect is characteristic
only for IL1, TNFa, IL6, MCSF in severe systemic disease, for
example, sepsis (Doherty et al., 1992; Gheorghiță et al., 2015).
It has previously been shown that use of antibiotics from
different groups in various animal models leads to a significant
increase in the expression of genes for pro-inflammatory IFN-g,
TNF-a, IL-1b and IL-6, anti-inflammatory IL-4 and effector
cytokines of the Th17 cell subpopulations IL-17 and IL-23 (Sun
et al., 2019). Broad spectrum antibiotics have a relatively stronger
effect on the cytokine response in the colon (Strzepa et al., 2017).
In current research the values of the obtained cytokine profile
in feces are local and reflect the state of the intestinal mucosa and
lymphoid tissue associated with the gastrointestinal tract(Rakhim
M. Khaitov, 2019). In group AB, we observe a suppression of the
production of hematopoietic cytokines GCSF, Granulocyte
Macrophage Colony-Stimulating Factor (GMCSF), IL3, by day
10 of the study. Under the influence of mare’s milk, we observe an
increase in the production of hematopoietic cytokines GCSF,
GMCSF, IL3 on day 20 of the study. It is assumed that elevated
production of the latter cytokines contributes to the proliferation
and differentiation of granulocytes and monocytes, and as a result,
restoration of the body after a disease and increased immune
system responsiveness. The obtained numbers on day 60 of the
study show the normalization of the synthesis of cytokines in the
studied samples produced by the intestinal lymphoid system. This
is manifested by a self-regulating cascade of cytokines; in other
words, in response to the production of activation cytokines, the
intestinal lymphoid cells begin to produce inhibitory cytokines. In
response to the activation of hematopoietic cytokines, an increase
in the production of hematopoiesis inhibitors (TNFa, MIP1a) is
observed. In contrast, indicators remain reduced until day 60 of
the study in the AB group.
IL1 and TNFa are cytokines of primary (pre-immune)
inflammation and act locally. They are necessary for the
immune response mechanism to present the antigen to T-
lymphocytes, promote their migration to regional lymph nodes,
and create conditions for a lymphocytic immune response
(Khaitov, 2019). These cytokines protect the primary link of the
immune system and also include IL6 and IL8. The increase in
IL1a production is balanced by the production of the endogenous
anti-inflammatory agent IL1RA, which is its antagonist and limits
the damaging effect of inflammatory processes on cells and tissues
of the body. By the end of the study, no significant shifts were
observed in the restoration of the cytokine profile in the AB group.
In conclusion, it seems that this prebiotic prevents possible
fluctuations in the activity of cytokines and immunoglobulins
associated with the action of the antibiotic.
Our study has several limitations. Due to our strict inclusion
criteria, aiming for a clinically homogeneous proband set with no
previous antibiotic exposure during the three months prior to
inclusion, sample size is very small, therefore the results should
be interpreted with caution. Thus we conceive of this study as aFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 9hypothesis-generating pilot. However, given the stringency with
which our tests were performed, for those few features where
statistical significance could still be concluded, we consider those
reliable, with impact of low power seen in how few such findings
pass all tests. Second, we employed division of subjects into two
groups, control and MM, to illustrate the influence of MM on gut
microbiota. Here, bronchopneumonia and associated
pathological processes equally occur in both groups, as does
standard treatment (i.e. the antibiotic intervention). Thus, our
findings reflect the impact of MM under circumstances of disease
being treated, rather than necessarily being representative of
what MM would do in healthy subjects. We do not consider this
a true limitation, however, as it represents the use case for which
we seek to evaluate impact of MM administration. Third, in our
study there were no probands where we could investigate the
effect of MM in a healthy group, and as such, we cannot
distinguish microbiome changes from MM alone from those
associated with microbiome restoration following antibiotics-
induced disruption via MM. As such, our results are ambiguous
with regards to whether observed patterns reflect the one or the
other possibility.
Thus, further studies are needed to clarify the mechanisms of
mare’s milk for local immunity. Additionally, little is known
about the interaction of the microbiota, its metabolites, and the
corresponding inflammatory/anti-inflammatory reactions in the
intestine mediated by cytokines. Moreover, how microbiota and
its metabolites affect host immunity during antibiotic therapy
remains to be explored.CONCLUSION
This pilot study on the impact of mare’s milk consumption
reveals it to be well tolerated in children concurrently receiving
antibiotic treatment and suggests positive effects on recovery of
the gut microbiome following such perturbation. Future studies
with larger sample numbers will be necessary to understand in
more detail the effects of mare’s milk on protecting and restoring
the microbiome, as well as on the immunological response
beyond the here studied age category.DATA AVAILABILITY STATEMENT
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